Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT05818683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05818683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
April 26, 2023
Completion date
May 23, 2028
Enrollment
300 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate neoplasms, metastatic hormone-sensitive prostate cancer